Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Dermatitis atopic · Cancer

Sanofi-Aventis U.S

Sanofi-aventis Healthcare Pty Ltd

Sanofi-Aventis U.S clinical programs — 117 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Bridgewater, USA HQ
177 Employees
TGA registrant Type
Company details
Status
Public
HQ
Bridgewater, USA
Employees
177
Programs
117
Drugs
148
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Sanofi-Aventis U.S projects

117 ClinicalTrials.gov programs sponsored by Sanofi-Aventis U.S.

Sanofi-Aventis U.S has 117 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

117 programs

Clinical programs

Page 2 of 3

  1. riliprubart

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases.

    phase 3 small molecule active

    1 trial

  2. ACT16146

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  3. ACT16482-01

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  4. ACT16482-03

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  5. ACT16482-04

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  6. ACT16482-05

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  7. ACT16482-06

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  8. ACT16753

    Sanofi-aventis Healthcare Pty Ltd

    Multiple sclerosis

    phase 2 small molecule active

    1 trial

  9. ACT16877

    Sanofi-aventis Healthcare Pty Ltd

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  10. ACT17453

    Sanofi-aventis Healthcare Pty Ltd

    Cancer - Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  11. ACT17967

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis

    phase 2 small molecule active

    1 trial

  12. ACT18064

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 2 other active

    1 trial

  13. ACT18207

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial

  14. ACT18301

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 small molecule active

    1 trial

  15. Amlitelimab, Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 small molecule active

    1 trial

  16. BEX17850

    Sanofi-aventis Healthcare Pty Ltd

    Healthy volunteers

    phase 2 other active

    1 trial

  17. Balinatunfib, Not the same excipients as test

    Sanofi-aventis Healthcare Pty Ltd

    Crohn's disease, Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  18. DRI17476

    Sanofi-aventis Healthcare Pty Ltd

    Type 1 diabetes mellitus

    phase 2 other active

    1 trial

  19. DRI17821

    Sanofi-aventis Healthcare Pty Ltd

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  20. DRI17849

    Sanofi-aventis Healthcare Pty Ltd

    Psoriasis

    phase 2 small molecule active

    1 trial

  21. DRI17963

    Sanofi-aventis Healthcare Pty Ltd

    Coeliac disease

    phase 2 small molecule active

    1 trial

  22. DRI18180

    Sanofi-aventis Healthcare Pty Ltd

    Alopecia areata

    phase 2 small molecule active

    1 trial

  23. DRI18450

    Sanofi-aventis Healthcare Pty Ltd

    Crohn’s disease

    phase 2 small molecule active

    1 trial

  24. DRI19220

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis suppurativa

    phase 2 other active

    1 trial

  25. Frexalimab, Matched Placebo for Test

    Sanofi-aventis Healthcare Pty Ltd

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  26. INBRX-101 Concentrate for Solution for Infusion 50mg/ml

    Sanofi-aventis Healthcare Pty Ltd

    Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

    phase 2 small molecule active

    1 trial

  27. INBRX101-01-201

    Sanofi-aventis Healthcare Pty Ltd

    Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

    phase 2 small molecule active

    1 trial

  28. Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  29. Itepekimab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Bronchiectasis

    phase 2 small molecule active

    1 trial

  30. LTS17231

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 other active

    1 trial

  31. LTS17704

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  32. Match placebo to test product, Balinatunfib

    Sanofi-aventis Healthcare Pty Ltd

    Crohn's disease

    phase 2 small molecule active

    1 trial

  33. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial

  34. Matched placebo for test product, SAR444336

    Sanofi-aventis Healthcare Pty Ltd

    Digestive system diseases

    phase 2 small molecule active

    1 trial

  35. Matched, SAR444656

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

  36. Not the same excipients as Test, Balinatunfib

    Sanofi-aventis Healthcare Pty Ltd

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  37. Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    Warm autoimmune hemolytic anemia

    phase 2 small molecule active

    1 trial

  38. Rilzabrutinib, Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 2 small molecule active

    1 trial

  39. SAR421869

    Sanofi-aventis Healthcare Pty Ltd

    Usher's syndrome

    phase 2 small molecule active

    1 trial

  40. SAR422459

    Sanofi-aventis Healthcare Pty Ltd

    Congenital, hereditary and neonatal diseases

    phase 2 small molecule active

    1 trial

  41. SAR442970, NANOBODY® Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  42. SAR443765 / LUNSEKIMIG

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 2 small molecule active

    1 trial

  43. SAR443765 / LUNSEKIMIG, Matched Placebo to Test

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

  44. SAR444656, Matched Placebo

    Sanofi-aventis Healthcare Pty Ltd

    hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  45. SAR445761 - belumosudil, belumosudil

    Sanofi-aventis Healthcare Pty Ltd

    Chronic graft versus host disease.

    phase 2 small molecule active

    1 trial

  46. TCD17197

    Sanofi-aventis Healthcare Pty Ltd

    Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasia

    phase 2 small molecule active

    1 trial

  47. TCD17620

    Sanofi-aventis Healthcare Pty Ltd

    Solid tumor

    phase 2 small molecule active

    1 trial

  48. TED14856

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Sanofi-Aventis U.S have?

117 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.